Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend. (12th February 2023)

• Record Type: Journal Article
• Authors: Cosman, Felicia; Hans, Didier; Shevroja, Enisa; Wang, Yamei; Mitlak, Bruce
• Is Part Of: Journal of bone and mineral research. Volume 38:Number 4(2023)
• Page Start: 464
• Page End: 470
• Publication Date: 2023-02-12
• Subjects: ANALYSIS/QUANTITATION OF BONE -- DXA -- CLINICAL TRIALS -- OSTEOPOROSIS -- ANABOLICS; Bones -- Metabolism -- Periodicals; Mineral metabolism -- Periodicals; 612.392
• DOI: 10.1002/jbmr.4764
• Languages: English
• ISSNs: 0884-0431

Abstract

ABSTRACT: Although bone mineral density (BMD) is a predictor of fracture, many fractures occur in women with T ‐scores > −2.5. Bone microarchitecture, assessed by trabecular bone score (TBS), predicts fracture risk independent of BMD. We evaluated whether abaloparatide improves TBS and whether TBS trends were associated with vertebral fracture risk reduction. Women with osteoporosis randomized to abaloparatide or placebo for 18 months (ACTIVE), followed by alendronate for 24 months (ACTIVExtend), with evaluable TBS, were included in this post hoc analysis ( N = 911). TBS was calculated from spine BMD scans using an algorithm adjusted for tissue thickness (TBSth ) at baseline, 6, 18, and 43 months. Mean increments in TBSth from baseline within and between treatment groups, proportion of women with TBSth increments above least significant change (LSC) and proportion with degraded TBSth (<1.027) were calculated. Risk estimates for vertebral fracture were compared using binary logistic regressions adjusted for baseline age and spine BMD. At baseline, 42% had degraded TBSth . Mean TBSth increased 4% after 18 months abaloparatide ( p < 0.001) and was unchanged with placebo. After 2 subsequent years of alendronate, the total cumulative TBSth increase was 4.4% with abaloparatide/alendronate and 1.7% with placebo/alendronate (group difference, p < 0.001). At 43 months, the proportion of women with degraded TBSth had declined to 21% with abaloparatide/alendronate and 37% with placebo/alendronate ( p < 0.05). An increase in TBSth ≥ LSC was observed in 50% of abaloparatide‐treated women at 18 months and was associated with decreased odds (odds ratio [OR]; 95% confidence interval [CI]) of vertebral fracture (0.19; 95% CI, 0.04–0.80, 6 months; 0.30; 95% CI, 0.11–0.79, 43 months). In conclusion, abaloparatide increased TBSth rapidly and progressively over 18 months and increments were maintained over 2 years with alendronate. TBSth increase was associated with vertebral fracture risk reduction. Microarchitectural improvement may be one mechanism by which abaloparatide strengthens vertebral bone. © 2023 Radius Health, Inc and The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR). Abstract : Mean TBSth (95% CI) percent change over time. Both ABL and PBO ended at 18 months (solid lines); at 19 months, all subjects started ALN for 24 months (dotted lines). * p < 0.001. ABL, abaloparatide; ALN, alendronate; CI, confidence interval; PBO, placebo; TBSth, trabecular bone score adjusted for tissue thickness.